Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | AR | P10275 | 4/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.42 |
| ▸ | OGA | O60502 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12744187 | 0.93 | NPC1 (0.48) | NPC1RAB9AMEN1ARLMNA | |
| SCHEMBL29102030 | 0.85 | — | — | |
| SCHEMBL160290 | 0.81 | NPC1 (0.53) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL15058848 | 0.81 | — | — | |
| Methane SCHEMBL27085490 | 0.79 | NPC1 (0.51) | NPC1RAB9AMEN1ARHPGD | |
| SCHEMBL13711959 | 0.79 | NPC1 (0.51) | NPC1RAB9AMEN1ARHPGD | |
| SCHEMBL233663 | 0.79 | NPC1 (0.51) | NPC1RAB9AMEN1ARHPGD | |
| Bromide SCHEMBL6317924 | 0.79 | NPC1 (0.51) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL12744157 | 0.78 | NPC1 (0.41) | NPC1RAB9AMEN1HPGDGRM5 | |
| SCHEMBL5032 | 0.78 | NPC1 (0.50) | NPC1RAB9AMEN1HPGDGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118922081-A | Insect, acarina and nematode pest control | 先正达农作物保护股份公司 | 2024-11-08 | — | — | CN | claimed |
| US-20240092780-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | ANKH LIFE SCIENCES LIMITED (IE) | 2024-03-21 | — | — | US | claimed |
| CN-110431138-A | AR-V7 inhibitor | HOFFMANN LA ROCHE | 2019-11-08 | — | — | CN | claimed |
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | INCYTE HOLDINGS CORPORATION | 2006-11-09 | — | — | US | claimed |
| CN-1147493-C | Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analoges thereof | 3M | 2004-04-28 | — | — | CN | claimed |
| CN-1320126-A | Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2001-10-31 | — | — | CN | claimed |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | SEED THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4704836-A1 | HETEROAROMATIC INDOLESULFONAMIDES | Seed Therapeutics, Inc (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | ENANTA PHARM INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| CN-120192314-A | Aryl heterocycle Kv1.3 inhibitor and preparation method and application thereof | 上海深势唯思科技有限责任公司 | 2025-06-24 | — | — | CN | disclosed |
| EP-4554938-A1 | TYROSINE KINASE 2 INHIBITORS AND USES THEREOF | Biogen MA Inc. (US) | 2025-05-21 | — | — | EP | disclosed |
| CN-115403704-B | Process for producing latex composition for dip molding | 锦湖石油化学株式会社 | 2024-12-20 | — | — | CN | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| CN-1147493-C | Oxazolo, thiazolo and selenazolo [4,5-C]-quinolin-4-amines and analoges thereof | 3M | 2004-04-28 | — | — | CN | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| CN-1320126-A | Oxazolo, thiazolo and selenazolo [4, 5-C ] quinolin-4-amines and analogs thereof | 3M INNOVATIVE PROPERTIES CO (US) | 2001-10-31 | — | — | CN | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-1995015955-A1 | 2,4-DIAMINOTHIAZOLES AND THEIR PRODUCTION | BASF AKTIENGESELLSCHAFT (DE) | 1995-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252751-A1 | 3-Aminopyrrolidine derivaties as modulators of chemokine receptors | CCR2, CXCR3, CCR5 | NPC1 4033/4885RAB9A 1445/4885MEN1 4347/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | NPC1 4578/4885RAB9A 2421/4885MEN1 786/4885 |
| US-20250376452-A1 | 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors and Methods of Use Thereof | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885RAB9A 3762/4885MEN1 3138/4885 |
| US-20260116874-A1 | HETEROAROMATIC INDOLESULFONAMIDES | DCAF1, DCAF15, DDX39B | NPC1 1637/4885RAB9A 2243/4885MEN1 4259/4885 |
| US-12384753-B2 | 17-beta-hydroxysteroid dehydrogenase type 13 inhibitors and methods of use thereof | HSD17B1, HSD17B13, HSD17B3 | NPC1 472/4885RAB9A 3762/4885MEN1 3138/4885 |
| US-20240092780-A1 | ADDUCTS AND DIMER COMPOUNDS SYNTHESIZED USING GK METHOD | DRD2, HNMT, DRD1 | NPC1 2675/4885RAB9A 1429/4885MEN1 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.